Two remarkably sunny reports just in from the stormy seas of the drug business: Genentech and Johnson & Johnson reported solid second-quarter earnings. The moral of the story is familiar but worth repeating here: Biotech specialty drugs and diversified business lines are two good defenses against the problems facing the drug business these days.
Late yesterday, [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment